Drugs.com - Clinical Trials

Lilly's Oral GLP-1, Orforglipron, Showed Compelling Efficacy and a Safety Profile Consistent with Injectable GLP-1 Medicines, in Complete Phase 3 Results

INDIANAPOLIS, June 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and...

Jun 23, 2025 - 00:20
 0
Lilly's Oral GLP-1, Orforglipron, Showed Compelling Efficacy and a Safety Profile Consistent with Injectable GLP-1 Medicines, in Complete Phase 3 Results
INDIANAPOLIS, June 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from ACHIEVE-1, a Phase 3 trial evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and...
Read More

Tags:

Previous Article

Lilly's Once-Weekly Insulin Efsitora Alfa Demonstrated A1C Reduction and a Safet...

Next Article

Incyte Announces FDA Approval of Monjuvi (tafasitamab-cxix) in Combination with ...

Related Posts

Rilzabrutinib Granted Orphan Drug Designation in the US for Sickle Cell Disease

Rilzabrutinib Granted Orphan Drug Designation in the US...

Jun 3, 2025  0

Apnimed Announces Positive Topline Results in the First Landmark Phase 3 Clinical Trial of AD109, an Investigational Once-Daily Oral Pill for Obstructive Sleep Apnea

Apnimed Announces Positive Topline Results in the First...

May 20, 2025  0

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Discontinues Development of Oral GLP-1 Receptor ...

May 12, 2025  0